close

Fundraisings and IPOs

Date: 2011-04-11

Type of information: Grant

Company: Scil Proteins (Germany)

Investors: Investitionsbank Sachsen Anhalt (Germany)

Amount: €700K

Funding type: grant

Planned used:

Scil Proteins has received an award of public funding to further establish methods for the combination of Affilin®therapeutics with biological effectors. The Investitionsbank Sachsen Anhalt has provided the Company with €700K to fund relevant in-house research projects. Scil Proteins’ Affilin®therapeutics are so called scaffold proteins derived from the human serum protein Ubiquitin. Affilin®molecules are high affinity binders with excellent target specificity. The Affilin®platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months. Scil Proteins intends to advance into clinical development two Affilin®therapeutic candidates targeting cancer indications.

Others:

Therapeutic area: Cancer - Oncology

Is general: Yes